vs
Side-by-side financial comparison of Commercial Vehicle Group, Inc. (CVGI) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Commercial Vehicle Group, Inc. is the larger business by last-quarter revenue ($154.8M vs $129.7M, roughly 1.2× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -5.2%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -10.8%).
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
CVGI vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.8M | $129.7M |
| Net Profit | — | — |
| Gross Margin | 9.7% | 98.0% |
| Operating Margin | -1.2% | -25.0% |
| Net Margin | — | — |
| Revenue YoY | -5.2% | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.8M | $129.7M | ||
| Q3 25 | $152.5M | $164.9M | ||
| Q2 25 | $172.0M | $114.4M | ||
| Q1 25 | $169.8M | $81.7M | ||
| Q4 24 | $163.3M | $74.8M | ||
| Q3 24 | $171.8M | $62.9M | ||
| Q2 24 | $193.7M | $54.1M | ||
| Q1 24 | $194.6M | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-7.1M | $25.7M | ||
| Q2 25 | $-4.8M | $-12.8M | ||
| Q1 25 | $-4.3M | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.5M | $-54.8M | ||
| Q2 24 | $-1.6M | $-70.4M | ||
| Q1 24 | $2.9M | $-136.1M |
| Q4 25 | 9.7% | 98.0% | ||
| Q3 25 | 10.5% | 99.0% | ||
| Q2 25 | 11.4% | 98.7% | ||
| Q1 25 | 10.5% | 94.3% | ||
| Q4 24 | 8.0% | 96.6% | ||
| Q3 24 | 9.6% | 97.4% | ||
| Q2 24 | 10.6% | 96.2% | ||
| Q1 24 | 11.9% | 96.4% |
| Q4 25 | -1.2% | -25.0% | ||
| Q3 25 | -0.7% | 15.1% | ||
| Q2 25 | 0.5% | -11.1% | ||
| Q1 25 | 0.8% | -52.2% | ||
| Q4 24 | -3.2% | -81.2% | ||
| Q3 24 | -0.6% | -89.3% | ||
| Q2 24 | 0.5% | -125.1% | ||
| Q1 24 | 2.3% | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | -4.6% | 15.6% | ||
| Q2 25 | -2.8% | -11.1% | ||
| Q1 25 | -2.5% | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.5% | -87.1% | ||
| Q2 24 | -0.8% | -130.1% | ||
| Q1 24 | 1.5% | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $0.28 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.70 | ||
| Q2 24 | $-0.05 | $-0.91 | ||
| Q1 24 | $0.09 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $93.0M |
| Total DebtLower is stronger | $104.9M | — |
| Stockholders' EquityBook value | $133.4M | $114.8M |
| Total Assets | $391.7M | $605.2M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $104.9M | — | ||
| Q3 25 | $108.2M | — | ||
| Q2 25 | $118.2M | — | ||
| Q1 25 | $117.4M | — | ||
| Q4 24 | $135.5M | — | ||
| Q3 24 | $128.8M | — | ||
| Q2 24 | $142.0M | — | ||
| Q1 24 | $155.7M | — |
| Q4 25 | $133.4M | $114.8M | ||
| Q3 25 | $136.5M | $73.6M | ||
| Q2 25 | $142.6M | $32.7M | ||
| Q1 25 | $136.7M | $32.8M | ||
| Q4 24 | $135.6M | $59.1M | ||
| Q3 24 | $179.3M | $-30.5M | ||
| Q2 24 | $169.6M | $15.1M | ||
| Q1 24 | $175.5M | $74.1M |
| Q4 25 | $391.7M | $605.2M | ||
| Q3 25 | $400.3M | $538.6M | ||
| Q2 25 | $429.8M | $555.3M | ||
| Q1 25 | $419.8M | $548.8M | ||
| Q4 24 | $424.6M | $594.1M | ||
| Q3 24 | $495.3M | $504.4M | ||
| Q2 24 | $503.2M | $551.1M | ||
| Q1 24 | $509.2M | $663.5M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 1.00× | — | ||
| Q3 24 | 0.72× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 0.89× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | $60.7M |
| Free Cash FlowOCF − Capex | $8.7M | — |
| FCF MarginFCF / Revenue | 5.6% | — |
| Capex IntensityCapex / Revenue | 2.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.3M | $60.7M | ||
| Q3 25 | $-1.7M | $14.3M | ||
| Q2 25 | $18.9M | $5.0M | ||
| Q1 25 | $15.2M | $-42.2M | ||
| Q4 24 | $-26.6M | $-35.7M | ||
| Q3 24 | $-17.1M | $-42.5M | ||
| Q2 24 | $12.6M | $-40.2M | ||
| Q1 24 | $-2.4M | $-119.0M |
| Q4 25 | $8.7M | — | ||
| Q3 25 | $-3.5M | $14.2M | ||
| Q2 25 | $17.4M | — | ||
| Q1 25 | $11.4M | — | ||
| Q4 24 | $-30.6M | — | ||
| Q3 24 | $-20.3M | — | ||
| Q2 24 | $6.4M | $-40.3M | ||
| Q1 24 | $-7.4M | — |
| Q4 25 | 5.6% | — | ||
| Q3 25 | -2.3% | 8.6% | ||
| Q2 25 | 10.1% | — | ||
| Q1 25 | 6.7% | — | ||
| Q4 24 | -18.7% | — | ||
| Q3 24 | -11.8% | — | ||
| Q2 24 | 3.3% | -74.5% | ||
| Q1 24 | -3.8% | — |
| Q4 25 | 2.3% | — | ||
| Q3 25 | 1.2% | 0.1% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 1.9% | 0.0% | ||
| Q2 24 | 3.2% | 0.2% | ||
| Q1 24 | 2.6% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.79× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
